Plain English Summaries
Summaries of PSC research
We've collated our commentary and lay summaries of research below.
With the demand for liver transplants ever-increasing, scientists are looking into new ways of increasing the number of suitable donor livers for use.
New study is looking at a new MRCP technology that could aid PSC diagnosis and how progression of disease is measured.
PSC research priorities presented at the BASL Immune-Mediated Liver Disease Special Interest Group.
Survey results published: reducing the risk of cancer is important to people affected by PSC and they are interested in helping reduce the risks of PSC-related cancers.
Dr Roger Chapman takes a look at vancomycin and its potential use in PSC.
The new BSGUK-PSC Guidelines for the diagnosis and management of PSC have been published.
Your survey responses have been acted upon and heard.
We are working with researchers to remove the uncertainty around diagnosing PSC.
A new 2 year and 10 year UK-PSC risk score tool for PSC.
PSC Support represents patients at EMA meeting on development of medicines for PSC
Co-authored by PSC Support, an article about the role of inflammatory bowel disease (IBD) nurses was published.
We’re working with psychologists to improve wellbeing for people affected by PSC.
Results of another drug trial for PSC have now been published following preliminary results announced last year.
GS-9674 led to significant improvements in liver biochemistry and markers of cholestasis in PSC patients.
Colectomies and PSC transplant: end ileostomy compared to ileal-pouch anal anastomosis (IPAA).
First nationwide audit of IBD care delivery following liver transplantation for PSC.
New British Society of Gastroenterology (BSG) Guidelines have now been published.
The European Medicines Agency is evaluating clinical trial design in PSC.
New and exciting findings about the activity of the enzyme, VAP-1.
Update on pharmacotherapies (treatemnts) for cholestatic liver disease.